Developing small molecule therapeutics for Ebola hemorrhagic fever virus

开发埃博拉出血热病毒的小分子疗法

基本信息

  • 批准号:
    7940614
  • 负责人:
  • 金额:
    $ 97.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ebola virus (EBOV) causes periodic outbreaks of severe viral hemorrhagic fevers in Africa with high mortality rates in infected patients. EBOV is classified as a Category A bioweapons agent by the Centers for Disease Control and Prevention (CDC) because of its highly infectious nature. Currently, there is no FDA approved vaccine or antiviral drug that is effective against EBOV infections. Moreover, rapid progression of EBOV infection will offer little opportunity for developing acquired immunity in an infected population. Therefore, there is a critical need for development of effective antivirals to respond to EBOV outbreak or bioterrorist attack. EBOV infection is initiated by the fusion between viral and host cell membranes, which is mediated by the viral envelope glycoprotein (GP). This selective interaction between EBOV-GP and host cell surface receptor molecules is essential for the initiation and establishment of the infection. Blocking of EBOV entry will lead to suppression of viral infectivity early in its life cycle. Our goal is to develop small molecule inhibitors of EBOV infection that can be used either prophylactically to a potentially EBOV exposed population or therapeutically during the post-infection period. In preliminary studies of this project, we have identified eight EBOV entry inhibitors of different chemotypes, which are active against infectious EBOV (IC50 = 20 ?M) and have low selectivity indices. The potential inhibitors and their derivatives will be further optimized and characterized by medicinal chemistry to increase their anti-EBOV potency (IC50 <1 ?M), and selectivity indices (SI>10). In addition, we will continue to screen a large number of molecules in a search for inhibitors with higher selectivity to provide new entry points for chemical optimization. The research team represents a collaborative effort by four experienced research and drug discovery/development groups; 1)Microbiotix, Inc. will conduct the medicinal chemistry, initial biological assays, mechanism of action studies and in vitro ADME evaluation; 2) Southwest Foundation for Biomedical Research (SFBR) will conduct the in vitro and in vivo EBOV infection evaluation; 3) Univ. of Illinois at Chicago (UIC) will conduct the mechanism of action studies; and 4) the Harvard Medical School will conduct the EBOV-GP-receptor binding studies. The major milestone of this proposal is to select 2-3 EBOV entry inhibitor candidates that will be advanced to Investigational New Drug (IND) enabling toxicology and safety pharmacology studies. Therefore the specific aims of this application are to: 1. Screen compound libraries to identify selective noncytotoxic inhibitors of EBOV entry; 2. Optimize the potency and selectivity of hit compounds and validate their antiviral activities; 3. Determine the mechanism of action (MOA) of the initial hit series and prioritize screening hits; 4.Identify EBOV inhibitors with in vitro ADME properties suitable for i.v. and oral dosing; and 5. Evaluate EBOV inhibitors in a guinea pig model of EBOV infection.
描述(由申请人提供):埃博拉病毒(EBOV)在非洲引起严重病毒性出血热的周期性爆发,感染患者的死亡率很高。EBOV因其高度传染性被疾病控制和预防中心(CDC)列为a类生物武器制剂。目前,没有FDA批准的疫苗或抗病毒药物对EBOV感染有效。此外,EBOV感染的快速进展将使受感染人群很少有机会产生获得性免疫。因此,迫切需要开发有效的抗病毒药物来应对埃博拉病毒的爆发或生物恐怖袭击。EBOV感染是由病毒包膜糖蛋白(GP)介导的病毒与宿主细胞膜融合引发的。EBOV-GP与宿主细胞表面受体分子之间的这种选择性相互作用对于感染的开始和建立至关重要。阻断EBOV的进入将导致在其生命周期早期抑制病毒的传染性。我们的目标是开发EBOV感染的小分子抑制剂,既可以用于预防潜在的EBOV暴露人群,也可以用于感染后时期的治疗。在该项目的初步研究中,我们已经鉴定出8种不同化学型的EBOV进入抑制剂,它们对感染性EBOV有活性(IC50 = 20 ?M),选择性指数低。潜在抑制剂及其衍生物将进一步优化和药物化学表征,以提高其抗ebov效力(IC50 <1 ?M),选择性指数(SI bbb10)。此外,我们将继续筛选大量分子,寻找具有更高选择性的抑制剂,为化学优化提供新的切入点。该研究小组由四个经验丰富的研究和药物发现/开发小组共同努力;1)Microbiotix, Inc.将进行药物化学、初步生物学分析、作用机制研究和体外ADME评估;2)由西南生物医学研究基金会(SFBR)进行体外和体内EBOV感染评估;3)伊利诺伊大学芝加哥分校(UIC)开展行动机制研究;4)哈佛医学院将进行ebov - gp受体结合研究。该提案的主要里程碑是选择2-3个EBOV进入抑制剂候选物,这些候选物将进入新药研究阶段,进行毒理学和安全药理学研究。因此,此应用程序的具体目标是:1。筛选化合物文库以鉴定EBOV进入的选择性非细胞毒性抑制剂;2. 优化命中化合物的效价和选择性,验证其抗病毒活性;3. 确定初始热门系列的作用机制(MOA),并优先筛选热门产品;4.鉴定具有适合静脉和口服给药的体外ADME特性的EBOV抑制剂;和5。评估EBOV抑制剂在EBOV感染豚鼠模型中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Arnab Basu其他文献

Arnab Basu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Arnab Basu', 18)}}的其他基金

Developing small molecule therapeutics for Ebola hemorrhagic fever virus
开发埃博拉出血热病毒的小分子疗法
  • 批准号:
    8302453
  • 财政年份:
    2010
  • 资助金额:
    $ 97.6万
  • 项目类别:
Developing small molecule therapeutics for Ebola hemorrhagic fever virus
开发埃博拉出血热病毒的小分子疗法
  • 批准号:
    8495891
  • 财政年份:
    2010
  • 资助金额:
    $ 97.6万
  • 项目类别:
Developing small molecule therapeutics for Ebola hemorrhagic fever virus
开发埃博拉出血热病毒的小分子疗法
  • 批准号:
    8099426
  • 财政年份:
    2010
  • 资助金额:
    $ 97.6万
  • 项目类别:
Developing small molecule therapeutics for Ebola hemorrhagic fever virus
开发埃博拉出血热病毒的小分子疗法
  • 批准号:
    8681302
  • 财政年份:
    2010
  • 资助金额:
    $ 97.6万
  • 项目类别:
Identification of Novel Broad Spectrum Influenza Virus Inhibitors
新型广谱流感病毒抑制剂的鉴定
  • 批准号:
    7878358
  • 财政年份:
    2009
  • 资助金额:
    $ 97.6万
  • 项目类别:
Identification of Novel Broad Spectrum Influenza Virus Inhibitors
新型广谱流感病毒抑制剂的鉴定
  • 批准号:
    7482015
  • 财政年份:
    2008
  • 资助金额:
    $ 97.6万
  • 项目类别:
Identification of Novel Broad Spectrum Influenza Virus Inhibitors
新型广谱流感病毒抑制剂的鉴定
  • 批准号:
    8494526
  • 财政年份:
    2008
  • 资助金额:
    $ 97.6万
  • 项目类别:
Identification of Novel Broad Spectrum Influenza Virus Inhibitors
新型广谱流感病毒抑制剂的鉴定
  • 批准号:
    8394133
  • 财政年份:
    2008
  • 资助金额:
    $ 97.6万
  • 项目类别:
Identification of Novel Broad Spectrum Influenza Virus Inhibitors
新型广谱流感病毒抑制剂的鉴定
  • 批准号:
    7667978
  • 财政年份:
    2008
  • 资助金额:
    $ 97.6万
  • 项目类别:
Identification of Ebola Virus Entry Inhibitors
埃博拉病毒进入抑制剂的鉴定
  • 批准号:
    7155577
  • 财政年份:
    2006
  • 资助金额:
    $ 97.6万
  • 项目类别:

相似海外基金

Multi-component interventions to reducing unhealthy diets and physical inactivity among adolescents and youth in sub-Saharan Africa (Generation H)
采取多方干预措施减少撒哈拉以南非洲青少年的不健康饮食和缺乏身体活动(H 代)
  • 批准号:
    10106976
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    EU-Funded
Exploring the mental health and wellbeing of adolescent parent families affected by HIV in South Africa
探讨南非受艾滋病毒影响的青少年父母家庭的心理健康和福祉
  • 批准号:
    ES/Y00860X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    Fellowship
Decolonization, Appropriation and the Materials of Literature in Africa and its Diaspora
非洲及其侨民的非殖民化、挪用和文学材料
  • 批准号:
    EP/Y024516/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    Research Grant
Exploring "Actionable Information" for Learning Improvement in Rural East Africa: A Positive Deviance Approach
探索东非农村地区学习改进的“可行信息”:积极偏差方法
  • 批准号:
    24K00390
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Water stressed cities: individual choice, access to water and pathways to resilience in sub-Saharan Africa
缺水城市:撒哈拉以南非洲地区的个人选择、水资源获取和恢复力途径
  • 批准号:
    MR/X022943/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    Fellowship
Protecting Women from Economic shocks to fight HIV in Africa (POWER)
保护非洲妇女免受经济冲击,抗击艾滋病毒 (POWER)
  • 批准号:
    MR/Y003837/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    Fellowship
Tackling antimicrobial resistance across dentistry in Sub-Saharan Africa.
解决撒哈拉以南非洲牙科领域的抗菌素耐药性问题。
  • 批准号:
    MR/Y019695/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    Research Grant
ePowerCart - Affordable Mobile Clean Energy for Remote Communities in Rural Sub-Saharan Africa and India
ePowerCart - 为撒哈拉以南非洲和印度农村偏远社区提供经济实惠的移动清洁能源
  • 批准号:
    10076185
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    Collaborative R&D
The Open fracture National Evaluation (ONE) Study - South Africa: Improving outcomes in the care of open fractures in low resource settings
开放性骨折国家评估 (ONE) 研究 - 南非:改善资源匮乏地区开放性骨折的护理效果
  • 批准号:
    MR/Y00955X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    Fellowship
Recognising & supporting informal mhealth in Africa through grassroots interventions (REIMAGINE)
认识
  • 批准号:
    MR/Y015614/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.6万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了